CBD Oil, derived from agricultural hemp, has been widely recognized for its many benefits on human health. It has grown in popularity amongst the medical community as a key supplement for maintaining homeostasis. Because CBD oil has the ability to talk to nearly every organ system in the body via the Endocannabinoid System (ECS) this plant-based nutrient plays a key role in optimizing balance and enhancing quality of life.
Most human studies of CBD have been done on people who have seizures, and the FDA recently approved the first CBD-based drug, Epidiolex, for rare forms of epilepsy. Clinical trials for other conditions are promising, but tiny. In one Brazilian study published in 2011 of people with generalized social anxiety disorder, for example, taking a 600-mg dose of CBD (higher than a typical dose from a tincture) lessened discomfort more than a placebo, but only a dozen people were given the pill.
Naturally, the testimonies of these experts were based on a comprehensive literature review, an endeavor which we have also undertaken, albeit in a less official capacity. While many new products have been hailed as a panacea in their times, and many web sources certainly allude to this status for CBD, our objective was more modest – presenting ten possible benefits of cannabidiol where sufficient evidence exists to back up the claims.
Cannabidiol did not reduce responses to negative emotional stimuli or reduce anxiety in healthy participants, according to a study published in Cannabis and Cannabinoid Research in 2017. Researchers tested participants' responses to negative images or words and threatening emotional faces and sensitivity to social rejection after taking oral cannabidiol.
Instead, CBD acts as an agonist on an entirely different receptor called the 5-HT1A receptor, and this is how CBD actually works as an antidepressant with anti-anxiety and neuroprotective effects. It also serves as what is called an “allosteric modulator” of your opioid receptors, which is how it works to remove pain and reduce the effects of chronic inflammation. Other positive medical effects of CBD (there’s over 60 of them, if you care to read up on them here) are due to increased intracellular calcium release and agonism of another receptor called the PPAR-γ receptor.
I would never endorse anything that I don’t use and benefit from myself, and I can honestly say that this is the most absorbable form of CBD I’ve ever used, it allows me to get all the benefits of smoking weed without actually smoking weed, and it is exact stuff that I personally purchase for myself and that now lives in a special place in my pantry.
Several complexities of the eCB system may impact upon the potential of CBD and other CB1R-activating agents to serve as anxiolytic drugs. First, CB1R agonists, including THC and AEA, have a biphasic effect: low doses are anxiolytic, but higher doses are ineffective or anxiogenic, in both preclinical models in and humans (reviewed in [33, 45]). This biphasic profile may stem from the capacity of CB1R agonists to also activate TRPV1 receptors when administered at a high, but not low dose, as demonstrated for AEA . Activation of TRPV1 receptors is predominantly anxiogenic, and thus a critical balance of eCB levels, determining CB1 versus TRPV1 activation, is proposed to govern emotional behavior [27, 47]. CBD acts as a TRPV1 agonist at high concentrations, potentially by interfering with AEA inactivation . In addition to dose-dependent activation of TRPV1 channels, the anxiogenic versus anxiolytic balance of CB1R agonists also depends on dynamic factors, including environmental stressors [33, 49].
It is for this reason that all the finished hemp goods that you see for sale in America, from food products to clothing to building materials, are part of an imported hemp industry that has surpassed $688 million annually. The size of this import industry is one of the major catalysts for hemp legalization in the U.S. As a renewable source of a range of products, hemp provides an exciting new step in American agriculture.
Multiple sclerosis (MS). A prescription-only nasal spray product (Sativex, GW Pharmaceuticals) containing both 9-delta-tetrahydrocannabinol (THC) and cannabidiol has been shown to be effective for improving pain, muscle-tightness, and urination frequency in people with MS. This product is used in over 25 countries outside of the United States. But there is inconsistent evidence on the effectiveness of cannabidiol for symptoms of multiple sclerosis when it is used alone. Some early research suggests that using a cannabidiol spray under the tongue might improve pain and muscle tightness, but not muscle spasms, tiredness, bladder control, mobility, or well-being and quality of life in patients with MS.
Accordingly, CB1R activation has been suggested as a target for anxiolytic drug development [15, 43, 44]. Proposed agents for enhancing CB1R activation include THC, which is a potent and direct agonist; synthetic CB1R agonists; FAAH inhibitors and other agents that increase eCB availability, as well as nonpsychoactive cannabis phytocannabinoids, including CBD. While CBD has low affinity for the CB1R, it functions as an indirect agonist, potentially via augmentation of CB1R constitutional activity, or via increasing AEA through FAAH inhibition (reviewed in ).
So am I to assume, due to no response/deleted comment that my simple question was too difficult to answer? With all the technical & correct information you have on you GREAT website, can someone (?) not simply correct or acknowledge the FACT the your NOT using nano-particle size product? I am truly interesting (for my wife) in CBD, have done my research, and I love working with numbers which is why if found this discrepancy. Comments welcome, but avoidance is disturbing.